Early-phase psychiatric drug development programmes may appear successful while leaving foreseeable risks to later clinical development unresolved. Demonstrating an acceptable safety profile and predictable pharmacokinetics (PK) supports further development, but offers limited guidance on which dose is likely to engage relevant central nervous system (CNS) mechanisms in the patients most likely to benefit. Potentially hidden determinants of later failure include pharmacodynamic (PD) or PK variability, reliance on biomarkers unrelated to disease pathophysiology, and a mismatch between a drug’s mechanism of action (MoA) and the biology of the disease to be treated. Early, quantitative human pharmacology can help address these risks.
Interindividual differences in drug absorption, distribution and clearance can lead to variable drug exposures, while at similar drug exposures, differences in target sensitivity can lead to substantial variation in target engagement and downstream PD effects. A dose that produces clear effects in some participants may have little effect in others, while more sensitive participants may experience more robust responses or adverse effects. As a result, average group effects can obscure meaningful individual differences, and a dose selected from the group mean may be ineffective for some participants or poorly tolerated by others. CHDR uses pharmacometric approaches to characterise the exposure–response relationship across participants, helping to distinguish target-sensitivity differences from PK variability for dose selection, safety monitoring, and the design of later-phase trials.
Psychiatric drug development should establish in advance how the drug’s MoA is expected to affect a disease-relevant biological process, functional or regulatory domain, and ultimately symptoms. The key question is not simply whether a compound changes a drug-sensitive PD measure, but whether that effect lies on a plausible pathway from exposure and target engagement to an outcome relevant to the intended patient population. Broad exploratory panels may detect pharmacological effects with no established connection to disease pathophysiology. A sensitive but disease-irrelevant biomarker can suggest confirmation of a relevant drug effect without strengthening the therapeutic hypothesis for the particular drug. CHDR offers a broad range of drug-sensitive PD assessments, including neurophysiological and neuropsychological measures, electroencephalography, transcranial magnetic stimulation-related outcomes, neuroendocrine function, and tasks assessing core cognitive domains. Selecting measures that are both sensitive to the MoA and functionally relevant to the disease that is being targeted with the drug can strengthen the case that observed PD effects may actually be therapeutically relevant.
Even when pharmacological activity is both disease-relevant and sensitive to the drug’s MoA, it may not translate into efficacy if the mechanism does not match the pathophysiology of the enrolled patient. Symptom-defined psychiatric diagnoses can encompass different biological processes. A compound may therefore benefit a treatment-responsive subgroup while showing little average effect in an unselected population. Early patient studies using biomarkers can test whether pharmacological relationships observed in healthy participants also apply to the intended population and can inform prospective enrichment or stratification. The proposed link between MoA, treatment-relevant biology, and clinical phenotype should be specified in advance, and candidate markers should be sufficiently reproducible and validated for their intended use. This makes patient selection part of the therapeutic hypothesis and helps distinguish compound-level failure from a mismatch between mechanism and population.
Together, these questions support a staged evidence strategy: proof of pharmacology in healthy participants, followed by proof of mechanism and proof of concept in patients. Progression should require a safe dose that produces relevant, reproducible CNS activity; a patient population in which the biological hypothesis can be tested; and endpoints capable of detecting both mechanism-related PD effects and clinically meaningful change. Early dialogue with regulators can help align the evidence plan with the intended indication.
This approach cannot eliminate uncertainty about disease biology or emerging safety risks. It can, however, expose "hidden" assumptions about the drug and its target disease that, if left untested, could contribute to late-stage failure, and make negative results in subsequent development more interpretable.